Feldan Therapeutics has developed a protein-based technology platform, the Feldan Shuttle, for direct delivery of proteins inside cells.

The platform has been successfully used on numerous cell types and in several organs by local injection. The Feldan Shuttle allowed the delivery of active nucleases, transcription factors, antibodies and peptides, revealing its potential to cell-based treatments (ex vivo) and in vivo therapies.

This platform can overcome delivery obstacles in the context of therapeutic use by providing a safe and highly efficient approach that alleviates manipulation complexity and that is associated with low regulatory burden.